These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27901482)

  • 1. Hyperglycemia triggers HIPK2 protein degradation.
    Baldari S; Garufi A; Granato M; Cuomo L; Pistritto G; Cirone M; D'Orazi G
    Oncotarget; 2017 Jan; 8(1):1190-1203. PubMed ID: 27901482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis.
    Nardinocchi L; Puca R; Sacchi A; D'Orazi G
    Mol Cancer; 2009 Jan; 8():1. PubMed ID: 19128456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha.
    Nardinocchi L; Puca R; Sacchi A; Rechavi G; Givol D; D'Orazi G
    PLoS One; 2009 Aug; 4(8):e6819. PubMed ID: 19714248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIPK2-a therapeutical target to be (re)activated for tumor suppression: role in p53 activation and HIF-1α inhibition.
    Nardinocchi L; Puca R; Givol D; D'Orazi G
    Cell Cycle; 2010 Apr; 9(7):1270-5. PubMed ID: 20234185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counteracting MDM2-induced HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer cells.
    Nardinocchi L; Puca R; Givol D; D'Orazi G
    FEBS Lett; 2010 Oct; 584(19):4253-8. PubMed ID: 20849851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation.
    Nardinocchi L; Puca R; D'Orazi G
    Aging (Albany NY); 2011 Jan; 3(1):33-43. PubMed ID: 21248371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia suppresses chemotherapeutic drug-induced p53 Serine 46 phosphorylation by triggering HIPK2 degradation.
    Moehlenbrink J; Bitomsky N; Hofmann TG
    Cancer Lett; 2010 Jun; 292(1):119-24. PubMed ID: 20018442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIPK2 modulates p53 activity towards pro-apoptotic transcription.
    Puca R; Nardinocchi L; Sacchi A; Rechavi G; Givol D; D'Orazi G
    Mol Cancer; 2009 Oct; 8():85. PubMed ID: 19828042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage.
    Lazzari C; Prodosmo A; Siepi F; Rinaldo C; Galli F; Gentileschi M; Bartolazzi A; Costanzo A; Sacchi A; Guerrini L; Soddu S
    Oncogene; 2011 Dec; 30(48):4802-13. PubMed ID: 21602882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zyxin is a critical regulator of the apoptotic HIPK2-p53 signaling axis.
    Crone J; Glas C; Schultheiss K; Moehlenbrink J; Krieghoff-Henning E; Hofmann TG
    Cancer Res; 2011 Mar; 71(6):2350-9. PubMed ID: 21248071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How cells switch HIPK2 on and off.
    Sombroek D; Hofmann TG
    Cell Death Differ; 2009 Feb; 16(2):187-94. PubMed ID: 18974774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay between Mdm2 and HIPK2 in the DNA damage response.
    Zhang XP; Liu F; Wang W
    J R Soc Interface; 2014 Jul; 11(96):. PubMed ID: 24829283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis.
    Di Stefano V; Rinaldo C; Sacchi A; Soddu S; D'Orazi G
    Exp Cell Res; 2004 Feb; 293(2):311-20. PubMed ID: 14729469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations.
    Di Stefano V; Mattiussi M; Sacchi A; D'Orazi G
    FEBS Lett; 2005 Oct; 579(25):5473-80. PubMed ID: 16212962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis.
    Rinaldo C; Prodosmo A; Mancini F; Iacovelli S; Sacchi A; Moretti F; Soddu S
    Mol Cell; 2007 Mar; 25(5):739-50. PubMed ID: 17349959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tyrosine Kinase c-Abl Promotes Homeodomain-interacting Protein Kinase 2 (HIPK2) Accumulation and Activation in Response to DNA Damage.
    Reuven N; Adler J; Porat Z; Polonio-Vallon T; Hofmann TG; Shaul Y
    J Biol Chem; 2015 Jul; 290(27):16478-88. PubMed ID: 25944899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XAF1 directs apoptotic switch of p53 signaling through activation of HIPK2 and ZNF313.
    Lee MG; Han J; Jeong SI; Her NG; Lee JH; Ha TK; Kang MJ; Ryu BK; Chi SG
    Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15532-7. PubMed ID: 25313037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α.
    Chen P; Duan X; Li X; Li J; Ba Q; Wang H
    Oncogene; 2020 Apr; 39(14):2863-2876. PubMed ID: 32034309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.
    Puca R; Nardinocchi L; Givol D; D'Orazi G
    Oncogene; 2010 Aug; 29(31):4378-87. PubMed ID: 20514025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.